Fenoldopam

Fenoldopam

SCHEMBL29424282

Cl.Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD1

The experimentally established mechanism targets of Fenoldopam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 known ✓ P21728 17/20 0.97
DRD2 P14416 9/20 0.97
KDM4E B2RXH2 6/20 0.97
RECQL P46063 4/20 0.97
BLM P54132 4/20 0.97
CYP3A4 P08684 2/20 0.97
CYP2D6 P10635 2/20 0.97
NFKB1 P19838 2/20 0.97
THPO P40225 2/20 0.97
HIF1A Q16665 2/20 0.97
HSD17B10 Q99714 2/20 0.97
DRD3 P35462 2/20 0.97
MEN1 O00255 1/20 0.97
CYP2C9 P11712 1/20 0.97
TSHR P16473 1/20 0.97
CYP2C19 P33261 1/20 0.97
KMT2A Q03164 1/20 0.97
KDM1A O60341 1/20 0.97
HTR1A P08908 1/20 0.97
ADRA2A P08913 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fenoldopam SCHEMBL9157381 1.00 DRD1 (0.97) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL16241872 1.00 DRD1 (0.97) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL1815791 0.99 DRD1 (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL41214 0.99 DRD1 (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL9157427 0.99 DRD1 (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL34250 0.99 DRD1 (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL13287212 0.99 DRD1 (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL1319766 0.97 KDM4E (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL11215595 0.97 KDM4E (1.00) DRD1DRD2KDM4ERECQLBLM
Fenoldopam SCHEMBL3136078 0.93 GFER (0.91) DRD1DRD2KDM4ERECQLBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4706758-A2 METHODS FOR INHIBITING PHOSPHATE TRANSPORT Ardelyx, Inc. (US) 2026-03-11 EP disclosed
US-20240325487-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2024-10-03 US disclosed
US-11813304-B2 Compounds and methods for inhibiting phosphate transport ARDELYX, INC. (US) 2023-11-14 US disclosed
US-20230277523-A1 METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2023-09-07 US disclosed
EP-3884935-B1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX INC (US) 2023-06-14 EP disclosed
EP-3972599-A1 COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT Ardelyx, Inc. (US) 2022-03-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240325487-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC34A3, SLC34A2, SLC34A1 DRD1 4625/4885DRD2 4720/4885KDM4E 3713/4885
US-11813304-B2 Compounds and methods for inhibiting phosphate transport SLC34A3, SLC34A2, SLC34A1 DRD1 4625/4885DRD2 4720/4885KDM4E 3713/4885
US-20230277523-A1 METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC34A3, SLC34A2, SLC34A1 DRD1 4870/4885DRD2 4876/4885KDM4E 2140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.